AEON Biopharma, Inc.
AEON
$0.40
-$0.0093-2.27%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.63% | -8.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.09% | -48.25% | |||
| Operating Income | -41.09% | 48.25% | |||
| Income Before Tax | 133.74% | -103.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 133.74% | -103.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 133.74% | -103.76% | |||
| EBIT | -41.09% | 48.25% | |||
| EBITDA | -41.39% | 48.41% | |||
| EPS Basic | 133.41% | -103.70% | |||
| Normalized Basic EPS | -9.42% | -489.31% | |||
| EPS Diluted | 130.10% | -103.79% | |||
| Normalized Diluted EPS | -9.21% | -489.31% | |||
| Average Basic Shares Outstanding | 1.00% | 1.72% | |||
| Average Diluted Shares Outstanding | 1.18% | 1.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
